PMID- 28743857
OWN - NLM
STAT- MEDLINE
DCOM- 20180501
LR  - 20220113
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 23
DP  - 2017 Jul 26
TI  - The Clinical Signification of Claudin-11 Promoter Hypermethylation for Laryngeal 
      Squamous Cell Carcinoma.
PG  - 3635-3640
AB  - BACKGROUND Claudin-11 (CLDN11) is frequently silenced by its promoter 
      hypermethylation. Previous studies have shown that CLDN11 promoter 
      hypermethylation is a potential biomarker for diagnosing various cancers. The aim 
      of this study was to investigate CLDN11 promoter methylation and its potential 
      relevance to clinicopathologic features and prognosis of patients with laryngeal 
      squamous cell carcinoma (LSCC). MATERIAL AND METHODS Using the quantitative 
      methylation-specific polymerase chain reaction (qMSP), CLDN11 promoter 
      methylation was measured in 91 tumor tissues and their paired adjacent normal 
      tissues, and the relationship between CLDN11 methylation and clinicopathologic 
      features was evaluated. A receiver operating characteristic (ROC) curve was 
      created to assess diagnostic values, and the Kaplan-Meier survival analysis was 
      used to evaluate the association between CLDN11 methylation and prognosis of 
      patients with LSCC. RESULTS Our results showed significantly elevated promoter 
      methylation of CLDN11 in tumor tissues compared to their adjacent tissues 
      (p=1.227E-16). CLDN11 promoter methylation also increased in patients with lymph 
      node metastasis (p=0.009), advanced clinical stage (p=9.26E-06) and higher T 
      classification (p=0.003). The area under the ROC curve (AUC) of CLDN11 was 0.884 
      (95% CI=0.835-0.932, p<0.01). The Kaplan-Meier analysis indicated that high 
      CLDN11 promoter methylation levels were associated with poor overall survival of 
      LSCC patients (log-rank test, p=0.007). CONCLUSIONS We demonstrated that CLDN11 
      promoter hypermethylation is a frequent event in LSCC, and contributes to 
      metastasis and progression of LSCC. Thus, CLDN11 could be a potential biomarker 
      for diagnosis and prognosis of LSCC patients.
FAU - Shen, Zhisen
AU  - Shen Z
AD  - Department of Otolaryngology (Head and Neck Surgery), Ningbo Medical Center 
      Lihuili Hospital Affiliated to Ningbo University, Ningbo, Zhejiang, China 
      (mainland).
FAU - Cao, Bing
AU  - Cao B
AD  - Department of Otolaryngology, School of Medicine, Ningbo University, Ningbo, 
      Zhejiang, China (mainland).
FAU - Lin, Lexi
AU  - Lin L
AD  - Department of Otolaryngology, School of Medicine, Ningbo University, Ningbo, 
      Zhejiang, China (mainland).
FAU - Zhou, Chongchang
AU  - Zhou C
AD  - Department of Otolaryngology, School of Medicine, Ningbo University, Ningbo, 
      Zhejiang, China (mainland).
FAU - Ye, Dong
AU  - Ye D
AD  - Department of Otolaryngology (Head and Neck Surgery), Ningbo Medical Center 
      Lihuili Hospital Affiliated to Ningbo University, Ningbo, Zhejiang, China 
      (mainland).
FAU - Qiu, Shijie
AU  - Qiu S
AD  - Department of Otolaryngology (Head and Neck Surgery), Ningbo Medical Center 
      Lihuili Hospital Affiliated to Ningbo University, Ningbo, Zhejiang, China 
      (mainland).
FAU - Li, Qun
AU  - Li Q
AD  - Department of Otolaryngology (Head and Neck Surgery), Ningbo Medical Center 
      Lihuili Hospital Affiliated to Ningbo University, Ningbo, Zhejiang, China 
      (mainland).
FAU - Cui, Xiang
AU  - Cui X
AD  - Department of Otolaryngology (Head and Neck Surgery), Ningbo Medical Center 
      Lihuili Hospital Affiliated to Ningbo University, Ningbo, Zhejiang, China 
      (mainland).
LA  - eng
PT  - Journal Article
DEP - 20170726
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CLDN11 protein, human)
RN  - 0 (Claudins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics
MH  - Carcinoma, Squamous Cell/genetics
MH  - Claudins/*genetics
MH  - *DNA Methylation
MH  - Female
MH  - Head and Neck Neoplasms/genetics
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*genetics
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Promoter Regions, Genetic
MH  - Squamous Cell Carcinoma of Head and Neck
PMC - PMC5541974
COIS- Conflicts of interest None.
EDAT- 2017/07/27 06:00
MHDA- 2018/05/02 06:00
PMCR- 2017/07/26
CRDT- 2017/07/27 06:00
PHST- 2017/07/27 06:00 [entrez]
PHST- 2017/07/27 06:00 [pubmed]
PHST- 2018/05/02 06:00 [medline]
PHST- 2017/07/26 00:00 [pmc-release]
AID - 904751 [pii]
AID - 10.12659/msm.904751 [doi]
PST - epublish
SO  - Med Sci Monit. 2017 Jul 26;23:3635-3640. doi: 10.12659/msm.904751.